SCHEMBL3354638

SCHEMBL3354638

CCOC(=O)CN1CC(C(=O)N2CCC(C#N)(Cc3ccc(F)cc3)CC2)Oc2cc(OC)c(Cl)cc21

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.32
KMT2A Q03164 3/20 0.31
CPT1A P50416 1/20 0.31
MEN1 O00255 1/20 0.31
CCR1 P32246 2/20 0.31
PPARG P37231 1/20 0.31
PGR P06401 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31
DRD2 P14416 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
PPOX P50336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3358227 0.94 LMNA (0.34) ALDH1A1L3MBTL1TSHRLMNAKMT2A
SCHEMBL3355350 0.91 SIRT1 (0.34) ALDH1A1LMNAKMT2ACCR1CTSS
SCHEMBL3358591 0.90 ALDH1A1 (0.33) ALDH1A1L3MBTL1TSHRLMNAKMT2A
SCHEMBL3356436 0.90 KMT2A (0.34) ALDH1A1L3MBTL1TSHRLMNAKMT2A
SCHEMBL3354658 0.89 ALDH1A1 (0.33) ALDH1A1LMNACCR1CTSSCTSK
SCHEMBL3353011 0.88 LMNA (0.34) ALDH1A1L3MBTL1LMNACCR1CTSS
SCHEMBL3358681 0.88 LMNA (0.35) ALDH1A1L3MBTL1LMNAKMT2ACPT1A
SCHEMBL3355650 0.87 GRIN1 (0.32) ALDH1A1TSHRLMNACYP2C9CTSS
SCHEMBL3354045 0.87 ALDH1A1 (0.34) ALDH1A1L3MBTL1TSHRLMNAKMT2A
SCHEMBL3354390 0.87 CCR1 (0.33) ALDH1A1LMNACCR1PGRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010068881-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-06-17 WO disclosed
US-20100152160-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-06-17 US disclosed
US-20100152160-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-06-17 US disclosed
US-20100152160-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152160-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS CCR1, CCR4, CCR5 ALDH1A1 903/4885L3MBTL1 4318/4885TSHR 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.